Core Viewpoint - Shareholders Qilu Investment and Qingsong Investment plan to collectively reduce their holdings by no more than 4% of the company's shares [1] Summary by Relevant Categories Shareholder Actions - Qilu Investment intends to reduce its stake by up to 3%, with a maximum of 1% through centralized bidding and 2% via block trading [1] - Qingsong Investment plans to reduce its stake by up to 1% through centralized bidding [1] Timeline - The reduction period will be within three months starting from fifteen trading days after the announcement date [1]

Group 1 - The core point of the announcement is that shareholders Qi Lu Investment and Qingsong Investment plan to reduce their holdings in Jinkai Biotechnology (301509) by a total of up to 361.2 million shares, which represents 3% of the company's total share capital [1] - Qi Lu Investment intends to reduce its stake by up to 120.4 million shares through centralized bidding, accounting for 1% of the total share capital, and by up to 240.8 million shares through block trading, accounting for 2% of the total share capital [1] - Qingsong Investment plans to reduce its stake by up to 120.4 million shares through centralized bidding, also representing 1% of the total share capital [1] Group 2 - The reduction period for these share sales will be within three months starting from fifteen trading days after the announcement date [1]

金凯（辽宁）生命科技股份有限公司 关于公司股东减持股份的预披露公告 股东启鹭（厦门）股权投资合伙企业（有限合伙）、青岛青松创业投资集团 有限公司－青岛松凯创业投资企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）股东启鹭（厦门）股权 投资合伙企业（有限合伙）（以下简称"启鹭投资"）持有公司股份7,140,500股（占 公司总股本比例5.93%）。启鹭投资计划通过集中竞价和大宗交易方式减持公司股份不 超过3,612,000股（占公司总股本比例3%）。其中，通过集中竞价方式减持股份不超过 1,204,000股，减持比例不超过公司总股本的1%；通过大宗交易方式减持股份不超过 2,408,000股，减持比例不超过公司总股本的2%。集中竞价或大宗交易的减持期间为自 本减持计划公告之日起十五个交易日后的三个月内。 公司股东青岛青松创业投资集团有限公司－青岛松凯创业投资企业（有限合伙） （以下简称"青松投资"）持有公司股份4,801,374股（ ...

证券时报·数据宝统计，截至（6月3日）收盘，沪指报3361.98点，涨14.49点，涨幅为0.43%；深成指报 10057.17点，涨16.54点，涨幅为0.16%；创业板指报2002.70点，涨9.51点，涨幅为0.48%。个股方面， 今日78只A股换手率超过20%，其中，雄帝科技、新天地等2只个股换手率达五成以上，半数筹码易 主。（数据宝） | 603333 | 尚纬股份 | 8.75 | 21.49 | -2.34 | | --- | --- | --- | --- | --- | | 301509 | 金凯生科 | 39.00 | 21.42 | 4.78 | | 002537 | 海联金汇 | 9.16 | 21.27 | 9.96 | | 301137 | 哈焊华通 | 35.34 | 21.22 | 1.64 | | 000510 | 新金路 | 6.03 | 21.03 | 10.04 | | 605136 | 丽人丽妆 | 13.10 | 20.98 | -7.29 | | 920128 | 胜业电气 | 37.91 | 20.83 | -0.58 | | 002882 | 金龙羽 | 24 ...

证券代码：301509 证券简称：金凯生科 公告编号：2025-017 金凯（辽宁）生命科技股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 金凯（辽宁）生命科技股份有限公司（以下简称"公司"或"发行人"） 2024年年度权益分派方案已获2025年5月19日召开的2024年度股东会审议通过，现 将权益分派事宜公告如下： 一、股东会审议通过的利润分配方案情况 1、公司2024年度利润分配方案为：以截至2024年12月31日公司总股本 120,446,669股为基数，向全体股东每10股派发现金红利人民币4.00元（含税）， 合计派发现金红利人民币48,178,667.60元（含税）；不送红股；资本公积金不转 增股本；剩余未分配利润结转至以后年度。本次利润分配完成后，本年度累计现 金分红总额48,178,667.60元，占公司本年度合并报表归属于母公司所有者净利润 的124.79%。 率征收，本公司暂不扣缴个人所得税，待个人转让股票时，根据其持股期限计算 应纳税额【注】；持有首发后限售股、股权激励限售股及无限售流通股的证券 ...

Investment Rating - The report maintains a positive outlook on the innovative drug sector within the healthcare industry [1]. Core Insights - The pharmaceutical sector outperformed the CSI 300 index slightly, with the Shenwan Pharmaceutical and Biological Index rising by 1.27% from May 12 to May 16, 2025, and by 2.48% year-to-date, ranking 11th among 31 Shenwan primary industry indices [1][12]. - The current valuation of the pharmaceutical sector stands at 26.80 times (TTM overall method, excluding negative values), with a premium of 141.06% compared to the CSI 300 index [15]. - The innovative drug segment is experiencing a pullback due to U.S. President Trump's announcement regarding drug price reductions, but the report suggests that the actual implementation of such policies will be challenging and will not significantly impact Chinese innovative drug companies' international expansion [3][20]. Summary by Sections 1. Market Review - The pharmaceutical sector's performance from May 12 to May 16, 2025, showed a 1.27% increase, outperforming the CSI 300 index by 0.15 percentage points [10]. - Year-to-date, the sector has increased by 2.48%, surpassing the CSI 300 index by 3.64 percentage points [12]. 2. Key Events - On May 12, 2025, President Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S., potentially lowering prices by 30% to 80% [19]. 3. Industry Perspective - The innovative drug sector is expected to continue as a key investment theme for 2025, with a focus on international expansion and emerging markets, particularly in companies like Kexing Pharmaceutical [4][21]. - The report highlights that the ongoing collection and procurement policies in various pharmaceutical fields are accelerating, with potential growth in segments like insulin and orthopedics [4][21].

证券代码：301509 证券简称：金凯生科 公告编号：2025-016 金凯（辽宁）生命科技股份有限公司 2024 年度股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决议案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、召开时间： （1）现场会议时间：2025 年 5 月 19 日（星期一）下午 14：00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 5 月 19 日的交易时间，即 9:15-9:25、9:30—11:30 和 13:00— 15:00；通过深圳证券交易所互联网系统投票的具体时间为 2025 年 5 月 19 日 9:15—15:00。 2、召开地点：辽宁省阜新市阜蒙县伊吗图镇氟化工园区安仁路 6 号金凯（辽 宁）生命科技股份有限公司会议室。 5、主持人：董事长 FUMIN WANG（王富民）先生。 6、本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东 会规则》《深圳证券交易所创业板股票上市规则 ...

北京市中伦（青岛）律师事务所 北京市中伦（青岛）律师事务所 关于金凯（辽宁）生命科技股份有限公司 2024 年度股东会的 法律意见书 二〇二五年五月 关于金凯（辽宁）生命科技股份有限公司 在本法律意见书中，本所仅对本次股东会召集和召开的程序、出席本次股 东会人员资格和召集人资格及表决程序、表决结果是否符合有关法律、法规、 规范性文件及《公司章程》的规定发表意见，并不对本次股东会审议的议案内 容以及该等议案所表述的事实或数据的真实性和准确性发表意见。本所仅根据 现行有效的中国法律法规发表意见，并不根据任何中国境外法律发表意见。 本所依据相关法律、法规、规章及规范性文件和《公司章程》的有关规定 以及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定职责， 遵循了勤勉尽责和诚实信用原则，对公司本次股东会相关事项进行了充分的核 查验证，保证本法律意见书所认定的事实真实、准确、完整，对本次股东会所 发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏， 并承担相应法律责任。 本所同意将本法律意见书作为本次股东会的公告材料，随同其他会议文件 一并报送有关机构并公告。除此以外，未经本所同意，本法律意 ...

Group 1 - Lingyun Optics' actual controller promises not to reduce shareholdings for 12 months starting from July 7, 2025 [1] - Chengdi Xiangjiang's subsidiary signed a contract with China Mobile for a data center project worth 1.632 billion yuan, with a 92-day construction period starting April 30, 2025 [1] - Dingyang Technology launched a high-end arbitrary waveform generator with a maximum output frequency of 5 GHz, catering to communication, industrial, and research testing needs [2][3] Group 2 - Heng Rui Medicine completed a share repurchase plan, buying back 12.9051 million shares for 601 million yuan, representing 0.20% of total shares [4][5] - ST Xiangxue received approval for clinical trials of TAEST1901 injection for treating advanced gastric cancer [5] - Yuyue Medical's subsidiary received EU MDR certification for its AED product, valid until May 11, 2030 [6][7] Group 3 - HNA Holding reported a 10.33% year-on-year increase in passenger revenue kilometers for April [8] - Springhui Zhikong's subsidiary terminated its listing on the National Equities Exchange and Quotations [9] - Delin Hai's shareholder plans to reduce holdings by up to 3%, equating to 3.39 million shares [10] Group 4 - Weiye Co. announced that two shareholders plan to reduce their holdings by up to 2% [12] - Green Alliance Technology's major shareholder intends to reduce holdings by up to 3% [14] - Luzhou Development Group increased its stake in Luzhou Tianhua by 1.02%, acquiring 15.9557 million shares [16] Group 5 - Hualan Pharmaceutical's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan [17] - Ganfeng Lithium's directors and executives plan to invest 30.8 million yuan in Shenzhen Yichu [19] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project [20] Group 6 - Jinkai Biotechnology's Blue Zone Fund plans to reduce holdings by up to 3% [21] - Hangxin Technology's former controlling shareholder intends to reduce holdings by up to 3% [22] - Galaxy Magnet's director plans to reduce holdings by up to 0.79% [23] Group 7 - Zhuoyue Technology's controlling shareholder's shares will be auctioned due to judicial proceedings [24] - Xinwufeng is forming a joint venture with France's Coplison Group with a registered capital of 80 million yuan [25] - Zhongcheng Co. is planning to issue shares to acquire 100% of a clean energy company, leading to a temporary stock suspension [26][27]